Floatz logo

PERFLUTREN

Pulmonary Embolism

Thunder Bay Regional Health Research InstituteSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Pulmonary Embolism cohort.

Asset / SponsorPhaseRating
Apixaban
Medical University of Gdansk
Phase 3BB
Tranexamic Acid
Albert Einstein College of Medicine
Phase 4BB
FONDAPARINUX
Johns Hopkins University
Phase 2BB
HEPARIN
Johns Hopkins University
Phase 4B
Enoxaparin
Medical University of Gdansk
Phase 1/2B

View all 14 →

Same molecule, other indications

PERFLUTREN is also rated in:

Recurrent Renal Cell CarcinomaDormant
B
Indicative ·
60 / 100
View asset →
asthmaDormant
B
Indicative ·
60 / 100
View asset →
Kidney CancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →